1
|
Wilczek J, Jadczyk T, Wojakowski W, Gołba KS. Time-related factors predicting a positive response to cardiac resynchronisation therapy in patients with heart failure. Sci Rep 2023; 13:8524. [PMID: 37237039 PMCID: PMC10219980 DOI: 10.1038/s41598-023-35174-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2023] [Accepted: 05/14/2023] [Indexed: 05/28/2023] Open
Abstract
This study aimed to identify time parameters predicting favourable CRT response. A total of 38 patients with ischemic cardiomyopathy, qualified for CRT implantation, were enrolled in the study. A 15% reduction in indexed end-systolic volume after 6 months was a criterion for a positive response to CRT. We evaluated QRS duration, measured from a standard ECG before and after CRT implantation and obtained from mapping with NOGA XP system (AEMM); and the delay, measured with the implanted device algorithm (DCD) and its change after 6 months (ΔDCD); and selected delay parameters between the left and right ventricles based on AEMM data. A total of 24 patients presented with a positive response to CRT versus 9 non-responders. After CRT implantation, we observed differences between responders and non-responders group in the reduction of QRS duration (31 ms vs. 16 ms), duration of paced QRS (123 ms vs. 142 ms), and the change of ΔDCDMaximum (4.9 ms vs. 0.44 ms) and ΔDCDMean (7.7 ms vs. 0.9 ms). The difference in selected parameters obtained during AEMM in both groups was related to interventricular delay (40.3 ms vs. 18.6 ms). Concerning local activation time and left ventricular activation time, we analysed the delays in individual left ventricular segments. Predominant activation delay of the posterior wall middle segment was associated with a better response to CRT. Some AEMM parameters, paced QRS time of less than 120 ms and reduction of QRS duration greater than 20 ms predict the response to CRT. ΔDCD is associated with favourable electrical and structural remodelling.Clinical trial registration: SUM No. KNW/0022/KB1/17/15.
Collapse
Affiliation(s)
- Jacek Wilczek
- Department of Electrocardiology and Heart Failure, Medical University of Silesia, Katowice, Poland.
- Electrocardiology Department, Upper Silesian Medical Center, Katowice, Poland.
| | - Tomasz Jadczyk
- Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
- Third Department of Cardiology, Upper Silesian Medical Center, Katowice, Poland
- Interventional Cardiac Electrophysiology Group, International Clinical Research Center, St. Anne's University Hospital in Brno, Brno, Czech Republic
| | - Wojciech Wojakowski
- Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
- Third Department of Cardiology, Upper Silesian Medical Center, Katowice, Poland
| | - Krzysztof S Gołba
- Department of Electrocardiology and Heart Failure, Medical University of Silesia, Katowice, Poland
- Electrocardiology Department, Upper Silesian Medical Center, Katowice, Poland
| |
Collapse
|
2
|
Sedláček K, Polášek R, Jansová H, Grieco D, Kučera P, Kautzner J, Francis DP, Wichterle D. Inadvertent QRS prolongation by an optimization device-based algorithm in patients with cardiac resynchronization therapy. PLoS One 2022; 17:e0275276. [PMID: 36155997 PMCID: PMC9512171 DOI: 10.1371/journal.pone.0275276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Accepted: 09/13/2022] [Indexed: 11/22/2022] Open
Abstract
Background Device-based algorithms offer the potential for automated optimization of cardiac resynchronization therapy (CRT), but the process for accepting them into clinical use is currently still ad-hoc, rather than based on pre-clinical and clinical testing of specific features of validity. We investigated how the QuickOpt-guided VV delay (VVD) programming performs against the clinical and engineering heuristic of QRS complex shortening by CRT. Methods A prospective, 2-center study enrolled 37 consecutive patients with CRT. QRS complex duration (QRSd) was assessed during intrinsic atrioventricular conduction, synchronous biventricular pacing, and biventricular pacing with QuickOpt-proposed VVD. The measurements were done manually by electronic calipers in signal-averaged and magnified 12-lead QRS complexes. Results Native QRSd was 174 ± 22 ms. Biventricular pacing with empiric AVD and synchronous VVD resulted in QRSd 156 ± 20 ms, a significant narrowing from the baseline QRSd by 17 ± 27 ms, P = 0.0003. In 36 of 37 patients, the QuickOpt algorithm recommended left ventricular preexcitation with VVD of 42 ± 18 ms (median 40 ms; interquartile range 30–55 ms, P <0.00001). QRSd in biventricular pacing with QuickOpt-based VVD was significantly longer compared with synchronous biventricular pacing (168 ± 25 ms vs. 156 ± 20 ms; difference 12 ± 11ms; P <0.00001). This prolongation correlated with the absolute VVD value (R = 0.66, P <0.00001). Conclusions QuickOpt algorithm systematically favours a left-preexcitation VVD which translates into a significant prolongation of the QRSd compared to synchronous biventricular pacing. There is no reason to believe that a manipulation that systematically widens QRSd should be considered to optimize physiology. Device-based CRT optimization algorithms should undergo systematic mechanistic pre-clinical evaluation in various scenarios before they are tested in large clinical studies.
Collapse
Affiliation(s)
- Kamil Sedláček
- 1 Department of Internal Medicine–Cardiology and Angiology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic
- * E-mail:
| | - Rostislav Polášek
- Cardiology Department, Liberec Regional Hospital, Liberec, Czech Republic
| | - Helena Jansová
- Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - Domenico Grieco
- Department of Cardiovascular Sciences, Policlinico Casilino of Rome, Rome, Italy
| | - Pavel Kučera
- Cardiology Department, Liberec Regional Hospital, Liberec, Czech Republic
| | - Josef Kautzner
- Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - Darrel P. Francis
- International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, Hammersmith Hospital, London, United Kingdom
| | - Dan Wichterle
- Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 2 Department of Internal Cardiovascular Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic
| |
Collapse
|
3
|
Aimo A, Fabiani I, Vergaro G, Arzilli C, Chubuchny V, Pasanisi EM, Petersen C, Poggianti E, Taddei C, Pugliese NR, Bayes-Genis A, Lupón J, Giannoni A, Ripoli A, Georgiopoulos G, Passino C, Emdin M. Prognostic value of reverse remodelling criteria in heart failure with reduced or mid-range ejection fraction. ESC Heart Fail 2021; 8:3014-3025. [PMID: 34002938 PMCID: PMC8318429 DOI: 10.1002/ehf2.13396] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Revised: 04/14/2021] [Accepted: 04/19/2021] [Indexed: 12/20/2022] Open
Abstract
Aims Reverse remodelling (RR) is the recovery from left ventricular (LV) dilatation and dysfunction. Many arbitrary criteria for RR have been proposed. We searched the criteria with the strongest prognostic yield for the hard endpoint of cardiovascular death. Methods and results We performed a systematic literature search of diagnostic criteria for RR. We evaluated their prognostic significance in a cohort of 927 patients with LV ejection fraction (LVEF) < 50% undergoing two echocardiograms within 12 ± 2 months. These patients were followed for a median of 2.8 years (interquartile interval 1.3–4.9) after the second echocardiogram, recording 123 cardiovascular deaths. Two prognostic models were defined. Model 1 included age, LVEF, N‐terminal pro‐B‐type natriuretic peptide, ischaemic aetiology, cardiac resynchronization therapy, estimated glomerular filtration rate, New York Heart Association, and LV end‐systolic volume (LVESV) index, and Model 2 the validated Cardiac and Comorbid Conditions Heart Failure score. We identified 25 criteria for RR, the most used being LVESV reduction ≥15% (12 studies out of 42). In the whole cohort, two criteria proved particularly effective in risk reclassification over Model 1 and Model 2. These criteria were (i) LVEF increase >10 U and (ii) LVEF increase ≥1 category [severe (LVEF ≤ 30%), moderate (LVEF 31–40%), mild LV dysfunction (LVEF 41–55%), and normal LV function (LVEF ≥ 56%)]. The same two criteria yielded independent prognostic significance and improved risk reclassification even in patients with more severe systolic dysfunction, namely, those with LVEF < 40% or LVEF ≤ 35%. Furthermore, LVEF increase >10 U and LVEF increase ≥1 category displayed a greater prognostic value than LVESV reduction ≥15%, both in the whole cohort and in the subgroups with LVEF < 40% or LVEF ≤ 35%. For example, LVEF increase >10 U independently predicted cardiovascular death over Model 1 and LVESV reduction ≥15% (hazard ratio 0.40, 95% confidence interval 0.18–0.90, P = 0.026), while LVESV reduction ≥15% did not independently predict cardiovascular death (P = 0.112). Conclusions Left ventricular ejection fraction increase >10 U and LVEF increase ≥1 category are stronger predictors of cardiovascular death than the most commonly used criterion for RR, namely, LVESV reduction ≥15%.
Collapse
Affiliation(s)
- Alberto Aimo
- Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.,Cardiology Division, Fondazione Toscana Gabriele Monasterio, Piazza Martiri della Libertà 33, Pisa, 56124, Italy
| | - Iacopo Fabiani
- Cardiology Division, Fondazione Toscana Gabriele Monasterio, Piazza Martiri della Libertà 33, Pisa, 56124, Italy
| | - Giuseppe Vergaro
- Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.,Cardiology Division, Fondazione Toscana Gabriele Monasterio, Piazza Martiri della Libertà 33, Pisa, 56124, Italy
| | | | - Vladyslav Chubuchny
- Cardiology Division, Fondazione Toscana Gabriele Monasterio, Piazza Martiri della Libertà 33, Pisa, 56124, Italy
| | - Emilio Maria Pasanisi
- Cardiology Division, Fondazione Toscana Gabriele Monasterio, Piazza Martiri della Libertà 33, Pisa, 56124, Italy
| | - Christina Petersen
- Cardiology Division, Fondazione Toscana Gabriele Monasterio, Piazza Martiri della Libertà 33, Pisa, 56124, Italy
| | - Elisa Poggianti
- Cardiology Division, Fondazione Toscana Gabriele Monasterio, Piazza Martiri della Libertà 33, Pisa, 56124, Italy
| | - Claudia Taddei
- Cardiology Division, Fondazione Toscana Gabriele Monasterio, Piazza Martiri della Libertà 33, Pisa, 56124, Italy
| | | | - Antoni Bayes-Genis
- CIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain.,Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
| | - Josep Lupón
- CIBER Cardiovascular, Instituto de Salud Carlos III, Madrid, Spain.,Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
| | - Alberto Giannoni
- Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.,Cardiology Division, Fondazione Toscana Gabriele Monasterio, Piazza Martiri della Libertà 33, Pisa, 56124, Italy
| | - Andrea Ripoli
- Cardiology Division, Fondazione Toscana Gabriele Monasterio, Piazza Martiri della Libertà 33, Pisa, 56124, Italy
| | - Georgios Georgiopoulos
- School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK
| | - Claudio Passino
- Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.,Cardiology Division, Fondazione Toscana Gabriele Monasterio, Piazza Martiri della Libertà 33, Pisa, 56124, Italy
| | - Michele Emdin
- Institute of Life Sciences, Scuola Superiore Sant'Anna, Pisa, Italy.,Cardiology Division, Fondazione Toscana Gabriele Monasterio, Piazza Martiri della Libertà 33, Pisa, 56124, Italy
| |
Collapse
|
4
|
Corbisiero R, Schmidt J, Muller D, Sookhu S, Shah M, Ochman A, Kazemain P. Paced or sensed conduction time to determine programming with cardiac resynchronization therapy: The PASED-CRT Trial. PACING AND CLINICAL ELECTROPHYSIOLOGY: PACE 2021; 44:967-972. [PMID: 33665812 DOI: 10.1111/pace.14212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Revised: 02/12/2021] [Accepted: 02/28/2021] [Indexed: 11/29/2022]
Abstract
BACKGROUND Cardiac resynchronization therapy (CRT) is a well-established treatment for patients with drug refractory heart failure. OBJECTIVES This study sought to compare the longest RVsense to LVsense activation time (sLAT) versus the longest RVpace to LVsense activation time (pLAT) as the programmed site for left ventricular (LV) pacing in CRT patients with quadripolar LV leads at 3 months. METHODS This single site, double-blinded, prospective trial, randomized patients 1:1 into the sLAT or pLAT group to determine response. LV pacing was programmed at implant and maintained through 3 months of follow-up. The 6-minute hall walk (6MHW) test, NYHA, Minnesota living with heart failure, and clinical composite score (CCS) at the 3 months was compared. RESULTS N = 92 patients (73M:19F age 66 ± 11.3 years) were randomized implanted and programmed per protocol. Baseline characteristics were comparable. N = 39 sLAT and N = 34 pLAT completed the 3-month visit for final analysis. Significant improvement from baseline to 3 months was seen in the sLAT group from 253.9 (+/-11.5) to 323.1 (+/-11.9) P = .001. Similarly, the pLAT group improved from 274.9 (+/-16.15) to 343.9 (+/-15.9) P = .003. The difference between these groups, however, did not reach significance (P = .86). The pLAT group demonstrated a higher responder rate of (71%) versus the sLAT group (64%) based on the CCS although not reaching significance (P = .56). CONCLUSIONS Use of both the pLAT and sLAT method of programming demonstrated significant improvement in 6MHW distance at 3 months with pLAT demonstrating a slightly higher responder rate based on CCS (P = .56). pLAT should be considered at minimum as equivalent in patients with no intrinsic conduction.
Collapse
Affiliation(s)
| | | | - David Muller
- Abbott Laboratories, Sicklerville, New Jersey, USA
| | - Sanjay Sookhu
- Deborah Heart & Lung Center, Browns Mills, New Jersey, USA
| | - Meet Shah
- Deborah Heart & Lung Center, Browns Mills, New Jersey, USA
| | | | | |
Collapse
|
5
|
Singh JP, Berger RD, Doshi RN, Lloyd M, Moore D, Stone J, Daoud EG. Targeted Left Ventricular Lead Implantation Strategy for Non-Left Bundle Branch Block Patients. JACC Clin Electrophysiol 2020; 6:1171-1181. [DOI: 10.1016/j.jacep.2020.04.034] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2019] [Revised: 04/20/2020] [Accepted: 04/30/2020] [Indexed: 10/23/2022]
|
6
|
Moubarak G, Sebag FA, Socie P, Villejoubert O, Louembe J, Ferchaud V. Interrelationships between interventricular electrical delays in cardiac resynchronization therapy. J Cardiovasc Electrophysiol 2020; 31:2405-2414. [PMID: 32562444 DOI: 10.1111/jce.14629] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/19/2020] [Revised: 06/07/2020] [Accepted: 06/14/2020] [Indexed: 11/28/2022]
Abstract
INTRODUCTION In cardiac resynchronization therapy, pacing the left ventricle (LV) at sites of prolonged electrical delay is associated with better outcomes. We sought to characterize the interrelationships between intrinsic, right-ventricular (RV)-paced, and LV-paced interventricular delays. METHODS AND RESULTS The following electrical timings were measured at implantation for all electrodes of the LV quadripolar leads: QLV, interventricular delay in intrinsic rhythm (RVs-LVs), in RV-paced rhythm (RVp-LVs), and in LV-paced rhythm (LVp-RVs). We included 32 patients (78% men, age 72 years, LV ejection fraction 29%, left bundle branch block 84%). QLV and RVs-LVs were correlated (R2 = .72, p < .0001), as were RVs-LVs and RVp-LVs (R2 = .27, p = .002) and RVp-LVs and LVp-RVs (R2 = .60, p < .001). Direction of activation along the four LV lead electrodes was concordant between RVs-LVs and RVp-LVs in only 17 (53%) patients. The latest-activated electrodes in RVs-LVs and RVp-LVs were concordant in 26 (81%) patients, adjacent in 3 (9%) patients, and remote in 3 (9%) patients. Biventricular-paced QRS duration varied by more than 10 ms between the two electrodes in half of the patients with dissimilar latest electrodes. Among the seven echocardiographic nonresponders at 6 months, the programmed electrode was remote from the latest electrode in RVs-LVs in five patients and in RVp-LVs in three patients. CONCLUSION Intrinsic and RV-paced interventricular electrical delays are correlated, but there is substantial heterogeneity between patients. The latest-activated electrode may be different between RVs-LVs and RVp-LVs, and this might have important implications in selecting the optimal LV vector.
Collapse
Affiliation(s)
- Ghassan Moubarak
- Department of Electrophysiology and Pacing, Centre Médico-Chirurgical Ambroise Paré, Neuilly-sur-Seine, France
| | - Frédéric A Sebag
- Département de Cardiologie Médicale, Institut Mutualiste Montsouris, Paris, France
| | - Pierre Socie
- Department of Cardiology, Centre Hospitalier de Chartres, Chartres, France
| | - Olivier Villejoubert
- Département de Cardiologie Médicale, Institut Mutualiste Montsouris, Paris, France
| | - Jules Louembe
- Department of Cardiology, Hôpital d'Instruction des Armées Percy, Clamart, France
| | - Virginie Ferchaud
- Department of Electrophysiology and Pacing, Centre Médico-Chirurgical Ambroise Paré, Neuilly-sur-Seine, France.,Department of Cardiology, Centre Hospitalier Universitaire de Caen Normandie, Caen, France
| |
Collapse
|
7
|
Singh JP, Abraham WT, Auricchio A, Delnoy PP, Gold M, Reddy VY, Sanders P, Lindenfeld J, Rinaldi CA. Design and rationale for the Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in non-responders and previously untreatable patients (SOLVE-CRT) trial. Am Heart J 2019; 217:13-22. [PMID: 31472360 DOI: 10.1016/j.ahj.2019.04.002] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/21/2018] [Accepted: 04/02/2019] [Indexed: 11/26/2022]
Abstract
BACKGROUND Cardiac resynchronization therapy (CRT) improves outcomes, functional capacity and quality of life in patients with heart failure. Despite two decades of experience with CRT, the rate of non-response remains approximately 30%. CRT efficacy is impacted by pacing location, which is anatomically limited in conventional systems. A new wireless endocardial left ventricular (LV) pacing system allows CRT without such limitations and has shown promise in open-label studies. The purpose of this study is to evaluate its use in a patient population with poor therapeutic alternatives. METHODS The SOLVE CRT study is an international, multi-center, randomized, double-blind, sham-controlled trial of patients with Class I and IIa indications for CRT who have either failed to respond to or have been unable to receive conventional CRT. Enrollment will comprise 350 patients implanted with the wireless CRT system randomized 1:1 to therapy on (Treatment) or therapy off (Control) for the six-month period over which trial primary endpoints will be evaluated. The primary safety endpoint will measure the proportion of patients free from system- and procedure-related complications. Primary efficacy endpoints will assess absolute change in LV end-systolic volume LVESV, proportion of patients reducing LVESV by ≥15% and clinical composite score for Treatment versus Control patients. Primary endpoints will be evaluated on an intention-to-treat basis, though per-protocol and as-treated analysis will also be performed. CONCLUSION SOLVE-CRT will quantify the safety and effectiveness of wireless CRT in non-responders to conventional CRT and indicated patients who have been unable to receive CRT via the usual transvenous approach.
Collapse
|
8
|
Kočková R, Sedláček K, Wichterle D, Šikula V, Tintěra J, Jansová H, Pravečková A, Langová R, Krýže L, El-Husseini W, Segeťová M, Kautzner J. Cardiac resynchronization therapy guided by cardiac magnetic resonance imaging: A prospective, single-centre randomized study (CMR-CRT). Int J Cardiol 2018; 270:325-330. [DOI: 10.1016/j.ijcard.2018.06.009] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/07/2018] [Revised: 05/22/2018] [Accepted: 06/04/2018] [Indexed: 10/14/2022]
|
9
|
Singh JP, Berger RD, Doshi RN, Lloyd M, Moore D, Daoud EG. Rationale and design for ENHANCE CRT: QLV implant strategy for non-left bundle branch block patients. ESC Heart Fail 2018; 5:1184-1190. [PMID: 30264456 PMCID: PMC6300807 DOI: 10.1002/ehf2.12340] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2018] [Revised: 05/31/2018] [Accepted: 06/22/2018] [Indexed: 11/10/2022] Open
Abstract
AIMS Historically, cardiac resynchronization therapy (CRT) response in non-left bundle branch block (non-LBBB) patients has been suboptimal in comparison with that observed in left bundle branch block patients. The electrical activation pattern of the left ventricle (LV) is different between these two QRS morphologies. Small non-randomized studies have suggested that targeting the LV wall with greatest electrical delay may be superior to conventional anatomical pacing from the lateral wall in non-LBBB patients. This article outlines the design and rationale of a prospective, randomized, pilot study, which assesses the effect of a non-traditional LV lead implant strategy on the clinical composite score after 12 months of follow-up in a non-LBBB patient population. METHODS All patients will receive an Abbott quadripolar CRT-D system (Quartet 1458Q LV lead with Unify Quadra™, Quadra Assura™ CRT-D or any market-approved CRT-D device with quadripolar pacing capabilities). Patients will be randomized in a 2:1 ratio between a QLV-based implant strategy vs. standard of care. Up to 250 patients will be enrolled in the study. CONCLUSIONS If the primary endpoint is achieved, this study will provide important information about reducing the non-responder rate in non-LBBB patients and provide further evidence for the QLV-based implant strategy.
Collapse
Affiliation(s)
| | | | - Rahul N Doshi
- University of Southern California, Los Angeles, CA, USA
| | | | - Douglas Moore
- St John Hospital and Medical Center, Detroit, MI, USA
| | | | -
- The Ohio State University, Columbus, OH, USA
| |
Collapse
|
10
|
Roubicek T, Wichterle D, Kucera P, Nedbal P, Kupec J, Sedlakova J, Cerny J, Stros J, Kautzner J, Polasek R. Left Ventricular Lead Electrical Delay Is a Predictor of Mortality in Patients With Cardiac Resynchronization Therapy. Circ Arrhythm Electrophysiol 2015; 8:1113-21. [DOI: 10.1161/circep.115.003004] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2015] [Accepted: 08/17/2015] [Indexed: 01/21/2023]
Affiliation(s)
- Tomas Roubicek
- From the Department of Cardiology, Regional Hospital Liberec, Liberec, Czech Republic (T.R., P.K., P.N., J. Kupec, J. Sedlakova, J.C., J. Stros, R.P.); Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (D.W., J. Kautzner); and Institute of Health Studies, Technical University of Liberec, Liberec, Czech Republic (D.W., J. Kautzner, R.P.)
| | - Dan Wichterle
- From the Department of Cardiology, Regional Hospital Liberec, Liberec, Czech Republic (T.R., P.K., P.N., J. Kupec, J. Sedlakova, J.C., J. Stros, R.P.); Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (D.W., J. Kautzner); and Institute of Health Studies, Technical University of Liberec, Liberec, Czech Republic (D.W., J. Kautzner, R.P.)
| | - Pavel Kucera
- From the Department of Cardiology, Regional Hospital Liberec, Liberec, Czech Republic (T.R., P.K., P.N., J. Kupec, J. Sedlakova, J.C., J. Stros, R.P.); Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (D.W., J. Kautzner); and Institute of Health Studies, Technical University of Liberec, Liberec, Czech Republic (D.W., J. Kautzner, R.P.)
| | - Pavel Nedbal
- From the Department of Cardiology, Regional Hospital Liberec, Liberec, Czech Republic (T.R., P.K., P.N., J. Kupec, J. Sedlakova, J.C., J. Stros, R.P.); Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (D.W., J. Kautzner); and Institute of Health Studies, Technical University of Liberec, Liberec, Czech Republic (D.W., J. Kautzner, R.P.)
| | - Jindrich Kupec
- From the Department of Cardiology, Regional Hospital Liberec, Liberec, Czech Republic (T.R., P.K., P.N., J. Kupec, J. Sedlakova, J.C., J. Stros, R.P.); Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (D.W., J. Kautzner); and Institute of Health Studies, Technical University of Liberec, Liberec, Czech Republic (D.W., J. Kautzner, R.P.)
| | - Jana Sedlakova
- From the Department of Cardiology, Regional Hospital Liberec, Liberec, Czech Republic (T.R., P.K., P.N., J. Kupec, J. Sedlakova, J.C., J. Stros, R.P.); Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (D.W., J. Kautzner); and Institute of Health Studies, Technical University of Liberec, Liberec, Czech Republic (D.W., J. Kautzner, R.P.)
| | - Jan Cerny
- From the Department of Cardiology, Regional Hospital Liberec, Liberec, Czech Republic (T.R., P.K., P.N., J. Kupec, J. Sedlakova, J.C., J. Stros, R.P.); Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (D.W., J. Kautzner); and Institute of Health Studies, Technical University of Liberec, Liberec, Czech Republic (D.W., J. Kautzner, R.P.)
| | - Jan Stros
- From the Department of Cardiology, Regional Hospital Liberec, Liberec, Czech Republic (T.R., P.K., P.N., J. Kupec, J. Sedlakova, J.C., J. Stros, R.P.); Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (D.W., J. Kautzner); and Institute of Health Studies, Technical University of Liberec, Liberec, Czech Republic (D.W., J. Kautzner, R.P.)
| | - Josef Kautzner
- From the Department of Cardiology, Regional Hospital Liberec, Liberec, Czech Republic (T.R., P.K., P.N., J. Kupec, J. Sedlakova, J.C., J. Stros, R.P.); Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (D.W., J. Kautzner); and Institute of Health Studies, Technical University of Liberec, Liberec, Czech Republic (D.W., J. Kautzner, R.P.)
| | - Rostislav Polasek
- From the Department of Cardiology, Regional Hospital Liberec, Liberec, Czech Republic (T.R., P.K., P.N., J. Kupec, J. Sedlakova, J.C., J. Stros, R.P.); Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (D.W., J. Kautzner); and Institute of Health Studies, Technical University of Liberec, Liberec, Czech Republic (D.W., J. Kautzner, R.P.)
| |
Collapse
|
11
|
Liang Y, Yu H, Zhou W, Xu G, Sun YI, Liu R, Wang Z, Han Y. Left Ventricular Lead Placement Targeted at the Latest Activated Site Guided by Electrophysiological Mapping in Coronary Sinus Branches Improves Response to Cardiac Resynchronization Therapy. J Cardiovasc Electrophysiol 2015; 26:1333-9. [PMID: 26249040 DOI: 10.1111/jce.12771] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2015] [Revised: 06/29/2015] [Accepted: 07/26/2015] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Electrophysiological mapping (EPM) in coronary sinus (CS) branches is feasible for guiding LV lead placement to the optimal, latest activated site at cardiac resynchronization therapy (CRT) procedures. However, whether this procedure optimizes the response to CRT has not been demonstrated. This study was to evaluate effects of targeting LV lead at the latest activated site guided by EPM during CRT. METHODS Seventy-six consecutive patients with advanced heart failure who were referred for CRT were divided into mapping (MG) and control groups (CG). In MG, the LV lead, also used as a mapping bipolar electrode, was placed at the latest activated site determined by EPM in CS branches. In CG, conventional CRT procedure was performed. Patients were followed for 6 months after CRT. RESULTS Baseline characteristics were comparable between the 2 groups. In MG (n = 29), EPM was successfully performed in 85 of 91 CS branches during CRT. A LV lead was successfully placed at the latest activated site guided by EPM in 27 (93.1%) patients. Compared with CG (n = 47), MG had a significantly higher rate (86.2% vs. 63.8%, P = 0.039) of response (>15% reduction in LV end-systolic volume) to CRT, a higher percentage of patients with clinical improvement of ≥2 NYHA functional classes (72.4% vs. 44.7%, P = 0.032), and a shorter QRS duration (P = 0.004). CONCLUSIONS LV lead placed at the latest activated site guided by EPM resulted in a significantly greater CRT response, and a shorter QRS duration.
Collapse
Affiliation(s)
- Yanchun Liang
- Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang, China
| | - Haibo Yu
- Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang, China
| | - Weiwei Zhou
- Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang, China
| | - Guoqing Xu
- Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang, China
| | - Y I Sun
- Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang, China
| | - Rong Liu
- Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang, China
| | - Zulu Wang
- Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang, China
| | - Yaling Han
- Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang, China
| |
Collapse
|
12
|
Polasek R, Wichterle D, Kautzner J. A new paradigm in cardiac resynchronization therapy? Am J Cardiol 2015; 115:1781. [PMID: 25907502 DOI: 10.1016/j.amjcard.2015.03.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/24/2015] [Accepted: 03/24/2015] [Indexed: 11/28/2022]
|
13
|
Upadhyay GA, Chatterjee NA, Kandala J, Friedman DJ, Park MY, Tabtabai SR, Hung J, Singh JP. Assessing mitral regurgitation in the prediction of clinical outcome after cardiac resynchronization therapy. Heart Rhythm 2015; 12:1201-8. [PMID: 25708879 DOI: 10.1016/j.hrthm.2015.02.022] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/17/2014] [Indexed: 12/12/2022]
Abstract
BACKGROUND Cardiac resynchronization therapy (CRT) has been shown to reduce mitral regurgitation (MR), although the clinical impact of this improvement remains uncertain. OBJECTIVES We sought to evaluate the impact of MR improvement on clinical outcome after CRT and to assess predictors and mechanism for change in MR. METHODS This was a cohort study of patients undergoing CRT for conventional indications with baseline and follow-up echocardiography (at 6 months). MR severity was classified into 4 grades. The primary end point was time to all-cause death or time to first heart failure (HF) hospitalization assessed at 3 years. RESULTS A total of 439 patients were included: median age was 70.2 years, 90 (20.5%) were women, 255 (58.1%) with ischemic cardiomyopathy, and mean QRS width was 162 ms. Worsening severity of baseline MR was independently predictive of HF or all-cause mortality (hazard ratio 1.33; 95% confidence interval 1.01-1.75; P = .042). Reduction in MR after CRT was significantly associated with lower HF hospitalization and improved survival (hazard ratio 0.65; 95% confidence interval 0.49-0.85; P = .002). Degree of baseline MR and longer surface QRS to left ventricular lead time were significant predictors of MR change. Patients with MR reduction exhibited lower mitral valve tenting area (P < .001) and coaptation height (P < .001) than those with stable or worsening MR, suggestive of improved ventricular geometry as a mechanism for change in MR. CONCLUSION Degree of baseline MR and change in MR after CRT predicted all-cause mortality and HF hospitalization at 3 years. Longer surface QRS to left ventricular lead time at implant may be a means to target MR improvement.
Collapse
Affiliation(s)
- Gaurav A Upadhyay
- Cardiac Arrhythmia Service, Massachusetts General Hospital, Boston, Massachusetts; Heart Rhythm Center, Section of Cardiology, University of Chicago, Chicago, Illinois
| | | | - Jagdesh Kandala
- Cardiac Arrhythmia Service, Massachusetts General Hospital, Boston, Massachusetts
| | - Daniel J Friedman
- Cardiac Arrhythmia Service, Massachusetts General Hospital, Boston, Massachusetts
| | - Mi-Young Park
- Echocardiography Laboratory of the Massachusetts General Hospital, Boston, Massachusetts
| | | | - Judy Hung
- Echocardiography Laboratory of the Massachusetts General Hospital, Boston, Massachusetts
| | - Jagmeet P Singh
- Cardiac Arrhythmia Service, Massachusetts General Hospital, Boston, Massachusetts.
| |
Collapse
|
14
|
Polasek R, Skalsky I, Wichterle D, Martinca T, Hanuliakova J, Roubicek T, Bahnik J, Jansova H, Pirk J, Kautzner J. High-density epicardial activation mapping to optimize the site for video-thoracoscopic left ventricular lead implant. J Cardiovasc Electrophysiol 2014; 25:882-888. [PMID: 24724625 PMCID: PMC4369134 DOI: 10.1111/jce.12430] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/25/2013] [Revised: 02/26/2014] [Accepted: 03/10/2014] [Indexed: 11/30/2022]
Abstract
Background The left ventricular (LV) lead local electrogram (EGM) delay from the beginning of the QRS complex (QLV) is considered a strong predictor of response to cardiac resynchronization therapy. We have developed a method for fast epicardial QLV mapping during video-thoracoscopic surgery to guide LV lead placement. Methods A three-port, video-thoracoscopic approach was used for LV free wall epicardial mapping and lead implantation. A decapolar electrophysiological catheter was introduced through one port and systematically attached to multiple accessible LV sites. The pacing lead was targeted to the site with maximum QLV. The LV free wall activation pattern was analyzed in 16 pre-specified anatomical segments. Results We implanted LV leads in 13 patients with LBBB or IVCD. The procedural and mapping times were 142 ± 39 minutes and 20 ± 9 minutes, respectively. A total of 15.0 ± 2.2 LV segments were mappable with variable spatial distribution of QLV-optimum. The QLV ratio (QLV/QRSd) at the optimum segment was significantly higher (by 0.17 ± 0.08, p < 0.00001) as compared to an empirical midventricular lateral segment. The LV lead was implanted at the optimum segment in 11 patients (at an adjacent segment in 2 patients) achieving a QLV ratio of 0.82 ± 0.09 (range 0.63–0.93) and 99.5 ± 0.6% match with intraprocedural mapping. Conclusion Video-thoracoscopic LV lead implantation can be effectively and safely guided by epicardial QLV mapping. This strategy was highly successful in targeting the selected LV segment and resulted in significantly higher QLV ratios compared to an empirical midventricular lateral segment.
Collapse
Affiliation(s)
- Rostislav Polasek
- Department of Cardiology, Regional Hospital Liberec, Husova, Liberec, Czech Republic
| | - Ivo Skalsky
- Cardiology Centre, Institute for Clinical and Experimental Medicine, Videnska, Prague, Czech Republic
| | - Dan Wichterle
- Cardiology Centre, Institute for Clinical and Experimental Medicine, Videnska, Prague, Czech Republic
| | - Tomas Martinca
- Cardiology Centre, Institute for Clinical and Experimental Medicine, Videnska, Prague, Czech Republic
| | - Jana Hanuliakova
- Department of Cardiology, Regional Hospital Liberec, Husova, Liberec, Czech Republic
| | - Tomas Roubicek
- Department of Cardiology, Regional Hospital Liberec, Husova, Liberec, Czech Republic
| | - Jan Bahnik
- Department of Cardiology, Regional Hospital Liberec, Husova, Liberec, Czech Republic
| | - Helena Jansova
- Cardiology Centre, Institute for Clinical and Experimental Medicine, Videnska, Prague, Czech Republic
| | - Jan Pirk
- Cardiology Centre, Institute for Clinical and Experimental Medicine, Videnska, Prague, Czech Republic
| | - Josef Kautzner
- Cardiology Centre, Institute for Clinical and Experimental Medicine, Videnska, Prague, Czech Republic
| |
Collapse
|
15
|
Affiliation(s)
- Chu-Pak Lau
- Cardiology Division, Department of Medicine, Queen Mary Hospital (C.-P.L., C.-W.S., H.-F.T.) and Research Center of Heart, Brain, Hormone and Healthy Ageing, Li Ka Shing Faculty of Medicine (C.-W.S., H.-F.T.), University of Hong Kong, Hong Kong SAR, China
| | | | | |
Collapse
|